Soni Medicare Limited reported a widening net loss and significant revenue contraction in its standalone financial results for the quarter ended June 30, 2026 (Q1FY27). The healthcare provider recorded a net loss of ₹119.85 lakh, compared to a net loss of ₹29.10 lakh in the same quarter last year. This deterioration coincided with a sharp decline in top-line growth, as revenue from operations fell 37.4% year-on-year to ₹455.27 lakh from ₹727.71 lakh in Q1FY26.

The financial performance reflects persistent pressure on margins, with total expenditure remaining elevated at ₹596.54 lakh despite the drop in revenue. Consequently, the company reported an EBITDA loss of ₹118.87 lakh for the quarter, expanding from an EBITDA loss of ₹29.35 lakh in the corresponding period of the previous fiscal year. Other income contributed ₹22.57 lakh to total revenue, which stood at ₹477.84 lakh.

Quarterly Financial Performance

In the preceding quarter (Q4FY26), Soni Medicare had reported a net loss of ₹36.63 lakh on revenue of ₹583.16 lakh. The current quarter’s results indicate a continued struggle to achieve operational profitability, with earnings per share (EPS) declining to -₹2.81 from -₹0.68 in the prior year.

What the Numbers Show

The divergence between revenue decline and expenditure levels highlights margin compression challenges. While revenue dropped by nearly 37%, total expenditure decreased by only 23.4% year-on-year. This mismatch resulted in the EBITDA loss more than quadrupling compared to the previous year, signaling that cost structures have not adjusted proportionately to the fall in operational income.

The results were reviewed by the Audit Committee and approved by the Board of Directors on August 14, 2026. The unaudited standalone financial results were filed with the stock exchanges in accordance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Soni Medicare Ltd's board of directors approved obtaining a bank guarantee from Punjab National Bank during a meeting held on July 23, 2026, at its registered office in Jaipur. The decision aims to facilitate the company's financial operations by securing the necessary credit support from the bank. The board authorized the company's directors and employees to execute all required documents, deeds, and agreements to avail this service.

In addition to the financial approval, the board empowered Managing Director Dr. Bimal Roy Soni to oversee all regulatory compliance related to the Rajasthan Government Health Scheme (RGHS). He is authorized to sign, execute, submit, and file all applications, forms, declarations, and agreements necessary for registration, empanelment, and renewals. This authorization ensures that the company can efficiently manage its obligations and correspondence under the scheme.

The meeting commenced at 1:00 P.M. and concluded at 2:00 P.M. with a vote of thanks. The decisions were taken in compliance with Regulation 30 of the SEBI (LODR) Regulations, 2025. The filing was submitted to the BSE Limited to inform the exchange of the board's outcome.

Key Approvals

The company's compliance officer, HARI KRISHAN TIWARI, confirmed the dissemination of this information to the stock exchange. The move to secure a bank guarantee and streamline RGHS compliance is expected to support the company's operational and administrative capabilities.